John Lonsdale, MD
Ophthalmology · Lewiston, MENPI 1669583662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 56.3% of the total. Reporting peaked in 2024 at $388 and has fallen 71.9% since, to $109 in 2025.
Across 79 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$785
- Sun Pharmaceutical Industries Inc.$190
- Alcon$133
- Bausch & Lomb Americas Inc.$101
- Oyster Point Pharma, Inc.$74
- Novartis$69
- plus $43 from 2 others
Across 9 payments — averaging $19,071 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$170K
- Alcon Research LLC$1K
What the payments were for
- Food & beverage$1,395100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $785 |
| Sun Pharmaceutical Industries Inc. | 10 | $190 |
| Alcon | 6 | $133 |
| Bausch & Lomb Americas Inc. | 5 | $101 |
| Oyster Point Pharma, Inc. | 3 | $74 |
| Novartis | 3 | $69 |
| Biotissue Holdings Inc. | 1 | $25 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
How this compares
$1,395 in reported general payments places this provider in the 75th percentile of 74 ophthalmology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 272 | $406,259 |
| LumiganBimatoprost | 559 | $356,264 |
| CombiganBrimonidine Tartrate/Timolol | 173 | $93,401 |
| XiidraLifitegrast | 55 | $86,886 |
| Alphagan PBrimonidine Tartrate | 59 | $31,770 |
| RhopressaNetarsudil Mesylate | 79 | $26,410 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 59 | $19,635 |
| Cyclosporine | 34 | $16,433 |
| Prednisolone Acetate | 443 | $12,077 |
| MoxifloxacinMoxifloxacin Hcl | 429 | $10,650 |
| Brinzolamide | 46 | $9,111 |
| AzoptBrinzolamide | 19 | $8,919 |
| Ketorolac Tromethamine | 434 | $7,831 |
| Latanoprost | 463 | $7,410 |
| Travoprost | 51 | $7,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $785 | $887,6931,063 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $101 | $92,55367 claims |
| AlconSimbrinza, Azopt | $133 | $28,55478 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 74 ophthalmology providers in Maine.
Other ophthalmology in Lewiston
- Charles ZacksPortland$36K
- Martin WhitakerNorway$5K
- Hallie HahnPortland$5K
- Curt YoungBangor$5K
- Samuel SolishPortland$4K
- Ravindra ShahPortland$4K
- Richard FrancePortland$4K
- Cynthia SelfBangor$3K
- Tamzid RahmanPortland$3K
- Oscar BatlleBangor$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.